Marie Rosenthal

1 week ago | pharmacypracticenews.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSThe CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the use of meningococcal groups A, B, C, W and Y vaccine (MenABCWY; Penmenvy, GSK) as part of the adolescent meningococcal vaccination schedule to protect against disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y). On Feb.

1 week ago | pharmacypracticenews.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIn a unanimous vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus vaccines to adults 50 to 59 years of age at increased risk for RSV-associated lower respiratory tract disease (LRTD). This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma,

1 week ago | idse.net | Marie Rosenthal

By Marie Rosenthal, MSIn a unanimous vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus vaccines to adults 50 to 59 years of age at increased risk for RSV-associated lower respiratory tract disease (LRTD). This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, cardiovascular disease and those in residential care.

1 week ago | pharmacypracticenews.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSA higher clinical cure rate was found among patients with serious gram-negative bacterial infections who received cefiderocol (Fetroja, Shionogi) as empiric therapy or for a documented infection than among those given it as salvage therapy, according to a presentation at ESCMID Global 2025, in Vienna (poster P2542).

1 week ago | specialtypharmacycontinuum.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIf given within 72 hours after clinical onset of COVID-19 in a household, oral ensitrelvir was effective in protecting household contacts from SARS-CoV-2 infection, according to a presentation at ESCMID Global 2025, in Vienna (abstract 03159). Protection was consistently seen in all at-risk groups studied, including older household contacts, according to Frederick G. Hayden, MD, the Stuart S.